You have 9 free searches left this month | to do more

ixazomib

Ixazomib is a drug used to treat Multiple Myeloma, Lymphoma, Advanced Solid Tumors, and other conditions. Ixazomib is being actively studied in 49 studies and prior, has been studied in 23.

Top SponsorsTop SitesTop Investigators
Millennium Pharmaceuticals, Inc.Dana Farber Cancer InstituteAjai Chari
TakedaMayo ClinicAjay Nooka
M.D. Anderson Cancer CenterMemorial Sloan Kettering Cancer CenterAndrew Yee, MD
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
E
Completed
  • Glioblastoma
  • Ixazomib
  • Atlanta, Georgia
    Emory University/Winship Cancer Institute
2021-03-02
Mar 2, 2021
M
Active, not recruiting
  • HIV
  • Ixazomib
  • Rochester, Minnesota
    Mayo Clinic
2021-02-08
Feb 8, 2021
T
Completed
  • Relapsed and/or Refractory Multiple Myeloma
  • Ixazomib
  • +2 more
  • Tokyo, Japan
    Takeda Selected Site
2021-06-03
Jun 3, 2021
D
Active, not recruiting
  • Smoldering Multiple Myeloma
  • Ixazomib
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-02-01
Feb 1, 2021
P
Recruiting
  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Ixazomib
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-02-17
Feb 17, 2021
E
Active, not recruiting
  • Mantle Cell Lymphoma
  • Ixazomib
  • Rituximab
  • Atlanta, Georgia
  • +1 more
2021-05-07
May 7, 2021
O
Recruiting
  • Newly Diagnosed Multiple Myeloma
  • West Hollywood, California
    James R Berenson, MD, Inc.
2020-10-23
Oct 23, 2020
H
Recruiting
  • Mantle Cell Lymphoma
  • Ixazomib
  • Busan, Western, Korea, Republic of
    Kosin University Gospel Hospital
2020-09-23
Sep 23, 2020
E
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
  • +3 more
2021-01-06
Jan 6, 2021
M
Completed
  • Myeloid Hematologic Malignancy
  • Lymphoid Hematologic Malignancy
  • Ixazomib
  • New York, New York
    Memorial Sloan Kettering Cancer Center
2021-09-03
Sep 3, 2021
H
Active, not recruiting
  • AML
  • AML, Adult
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Cancer Center
2021-09-01
Sep 1, 2021
P
Recruiting
  • Mantle-Cell Lymphoma
  • Atlanta, Georgia
  • +15 more
2021-07-26
Jul 26, 2021
M
Recruiting
  • Plasmacytoma
  • POEMS Syndrome
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2021-08-09
Aug 9, 2021
F
Recruiting
  • Hematopoietic Stem Cell Transplantation
  • Multiple Myeloma
  • Ixazomib
  • +3 more
  • Badalona, Spain
  • +7 more
2021-01-08
Jan 8, 2021
W
Recruiting
  • Systemic Sclerosis
  • +18 more
  • Ixazomib
  • Scottsdale, Arizona
    Mayo Clinic in Arizona
2021-04-30
Apr 30, 2021
M
Withdrawn
  • Liposarcoma
  • +4 more
  • New York, New York
    Columbia University Medical Center
2020-11-24
Nov 24, 2020
M
Recruiting
  • AL Amyloidosis
  • Boston, Massachusetts
  • +7 more
2021-07-13
Jul 13, 2021
T
Completed
  • Relapsed and/or Refractory Multiple Myeloma
  • Ixazomib
  • +2 more
  • Nagoya, Aichi, Japan
  • +20 more
2020-12-18
Dec 18, 2020
R
Active, not recruiting
  • Lymphoma, T-Cell, Peripheral
  • Chicago, Illinois
  • +6 more
2021-01-15
Jan 15, 2021
M
Recruiting
  • Metastatic Kidney Medullary Carcinoma
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-07-14
Jul 14, 2021
M
Completed
  • Advanced Solid Tumors
  • Lymphoma
  • IXAZOMIB
  • Cleveland, Ohio
    (unnamed)
2020-08-25
Aug 25, 2020
I
Recruiting
  • AL Amyloidosis
  • Ixazomib
  • +2 more
  • New York, New York
  • +3 more
2020-08-24
Aug 24, 2020
B
Active, not recruiting
  • B Cell Lymphoma
  • Lymphoma
  • Ixazomib
  • +2 more
  • Cleveland, Ohio
  • +1 more
2021-01-08
Jan 8, 2021
M
Active, not recruiting
  • Solid Tumors
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2020-02-11
Feb 11, 2020